Hepatoprotectors In The Treatment Of Nonalcoholic Fatty Liver Disease


L.A. Zvenigorodskaya, E.A. Cherkashova, N.G. Samsonova

Nonalcoholic fatty liver disease (NAFLD) is a major risk factor for cardiovascular disease. The article is dedicated to the classification, pathogenesis, diagnosis and treatment of NAFLD. Essential phospholipids are most appropriate in the treatment of steatosis, as well as more pronounced cytolytic syndrome. Non-alcoholic steatohepatitis with signs of cholestasis requires administration of ursodeoxycholic acid. Taking into account pathogenetic aspects, the complex hepatoprotective therapy of patients with NAFLD should include drugs normalizing the intestinal microflora (intestinal antiseptics, pre- and probiotics).

Similar Articles


Бионика Медиа